The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2021 | Targeted therapies for NSCLC
Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, discusses targeted therapies for non-small cell lung cancer (NSCLC). Currently, there are several approved drugs targeting frequent mutations in NSCLC. It is necessary to develop drugs targeting less common mutations in genes frequently mutated in NSCLC such as EGFR exon 20 mutations and HER2 exon 20 insertions. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.
